FINNENCE ▪ THE WIRE FILE
THE WIRE · № 65005
News▲ Bullish
Consano Bio Raises More Than $15 Million in Oversubscribed Financing to Advance C-1101 in Chronic Painful Lumbosacral Radiculopathy (Chronic Sciatica)
KINDNews
DIRECTION▲ Bullish
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-10-05 12:10 UTC
LAST UPDATE2026-10-05 12:10 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Oversubscribed private financing extends runway for a Phase 1 pain therapeutic, signaling investor appetite for the asset.
Consano Bio funds sciatica drug through Phase 1
CATALYST TO WATCH
Phase 1 clinical data in first half 2027
MAIN RISK
Early-stage drug may fail in trials
FULL DISPATCH
Proceeds will fund completion of the Phase 1 trial and continued development of C-1101, a potential first-in-class disease-modifying therapeutic Clinical data expected in 1H 2027 BURLINGTON, Mass., Oct. 5, 2026 /PRNewswire/ -- Consano Bio, Inc., a clinical-stage biotechnology company...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial2026-10-05 12:15 UTC
Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial2026-10-05 12:15 UTC
→CORRELATIONshares Healthcare
International Trichology Expert Dr. Kyjuan Brown Unveils AI Scalp Technology and Hair Loss Products at Global Beauty & Trichology Symposium2026-10-05 12:36 UTC
International Trichology Expert Dr. Kyjuan Brown Unveils AI Scalp Technology and Hair Loss Products at Global Beauty & Trichology Symposium2026-10-05 12:36 UTC
→CORRELATIONshares Healthcare
ATI Physical Therapy Launches Innovative Online Scheduling Platform to Make Accessing Care Faster and Easier2026-10-05 12:42 UTC
ATI Physical Therapy Launches Innovative Online Scheduling Platform to Make Accessing Care Faster and Easier2026-10-05 12:42 UTC
→CORRELATIONshares Healthcare
OMLYCLO® (omalizumab-igec), the first and only FDA-approved interchangeable biosimilar to XOLAIR®, now commercially available in the U.S.2026-10-05 12:45 UTC
OMLYCLO® (omalizumab-igec), the first and only FDA-approved interchangeable biosimilar to XOLAIR®, now commercially available in the U.S.2026-10-05 12:45 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line (1L) Platinum-based Chemotherapy in Participants With Ovarian Cancer — Genmab2026-10-05 12:00 UTC
New Phase 3 trial: Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line (1L) Platinum-based Chemotherapy in Participants With Ovarian Cancer — Genmab2026-10-05 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: Phase 3, Open-Label Extension Study of AMBTX-01 (Neridronate) for Complex Regional Pain Syndrome Type 1 — Ambros Therapeutics, Inc.2026-10-05 12:00 UTC
New Phase 3 trial: Phase 3, Open-Label Extension Study of AMBTX-01 (Neridronate) for Complex Regional Pain Syndrome Type 1 — Ambros Therapeutics, Inc.2026-10-05 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.